Drug compounder ImprimisRx — which made publicity in 2015 by offering a $1 version of Daraprim, the drug at the heart of Martin Shkreli’s price gouging escapades — has been handed another warning letter from the FDA over one of its production sites.
LEDGEWOOD, N.J.--(BUSINESS WIRE)--ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%.
ImprimisRx is in hot water with the FDA for false and misleading claims about its compounded drug for postoperative eye pain called Pred-Moxi-Brom.
Imprimis Rx LLC Receives FDA Warning Letter
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic?focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic medicines, IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis. The acquired products, which will be sold, marketed, and distributed through Harrow’s wholly owned subsidiary, ImprimisRx, combined with the Company’s existing ophthalmic?focused product portfolio, support Harrow’s growing ophthalmic surgical and acute care market presence.
FDA Issues Form 483 to Imprimis NJOF, -LLC
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced record results for the second quarter and first half ended June 30, 2021. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com.